| ID Source | ID |
|---|---|
| PubMed CID | 17231 |
| CHEMBL ID | 1328156 |
| CHEBI ID | 170073 |
| SCHEMBL ID | 503567 |
| Synonym |
|---|
| 4-octoxybenzoic acid |
| CHEBI:170073 |
| p-octyloxybenzoic acid |
| NCGC00091132-01 |
| p-n-octyloxybenzoic acid |
| ccris 4690 |
| nsc 142138 |
| 2493-84-7 |
| benzoic acid, p-(octyloxy)- |
| p-(octyloxy)benzoic acid |
| p-(n-octyloxy)benzoic acid |
| nsc-142138 |
| 4-octyloxybenzoic acid |
| nsc142138 |
| benzoic acid, 4-(octyloxy)- |
| p-octoxybenzoic acid |
| 4-(octyloxy)benzoic acid, 98% |
| 4-(octyloxy)benzoic acid |
| MLS002454443 , |
| smr001372025 |
| O0117 |
| 4-n-octyloxybenzoic acid |
| AKOS004908118 |
| NCGC00091132-02 |
| 04gd4oj7fu , |
| unii-04gd4oj7fu |
| cas-2493-84-7 |
| NCGC00258458-01 |
| dtxcid905807 |
| dtxsid1025807 , |
| tox21_200904 |
| A817563 |
| FT-0634326 |
| 4-octyloxy benzoic acid |
| p-octyloxy benzoic acid |
| 4-n-octoxybenzoic acid |
| 4-octyloxy-benzoic acid |
| bdbm74417 |
| cid_17231 |
| SCHEMBL503567 |
| CHEMBL1328156 |
| mfcd00013993 |
| p-(n-octoxy)benzoic acid |
| octyloxybenzoic acid, 4- |
| AS-59104 |
| 4-(n-octyloxy)benzoic acid |
| BBL102166 |
| STL555965 |
| Q27889401 |
| ooba |
| D91803 |
| 4-(octyloxy)benzoicacid |
| 4-(octyloxy)benzoic acid (en) |
| CS-0147091 |
| Class | Description |
|---|---|
| benzoic acids | Any aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 24.1568 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID588342 |
| interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 18.0758 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.0645 | 0.0007 | 14.5928 | 83.7951 | AID1259368 |
| AR protein | Homo sapiens (human) | Potency | 28.8429 | 0.0002 | 21.2231 | 8,912.5098 | AID743063 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 39.8107 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 33.9921 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 38.1549 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 48.0151 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 60.9591 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 2.4065 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 24.8000 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 38.4626 | 0.3758 | 27.4851 | 61.6524 | AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 60.4474 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 57.2063 | 0.0002 | 29.3054 | 16,493.5996 | AID1259248; AID588513; AID743069; AID743075; AID743078 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 20.0057 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID743212; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 47.0703 | 0.0010 | 19.4141 | 70.9645 | AID588537; AID743191 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 57.0660 | 0.0007 | 23.0674 | 1,258.9301 | AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.4802 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 60.9591 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 0.0020 | 0.3162 | 12.4435 | 31.6228 | AID924 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 32.6427 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.0008 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 29.8565 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 52.9853 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 37.6858 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 55.6219 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 39.8107 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 5.8048 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 3.9811 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 58.2144 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 0.0020 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 0.0020 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 3.9811 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 7.0795 | 0.0158 | 23.5273 | 44.6684 | AID651778 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 56.2341 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1147214 | Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 591 umol/kg/day administered through diet for 4 days | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6 | 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. |
| AID1147294 | Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 591 umol/kg/day administered through diet for 4 days | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6 | 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. |
| AID1147488 | Increase in cholesterol level in Wistar rat liver at 591 umol/kg/day administered through diet for 4 days | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6 | 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. |
| AID1400961 | Inhibition of germ tube formation in Candida albicans SC5314 assessed as yeast to hyphal conversion at 30 to 300 uM after 2 hrs by differential interference contrast microscopic analysis relative to control | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Efficient click chemistry towards fatty acids containing 1,2,3-triazole: Design and synthesis as potential antifungal drugs for Candida albicans. |
| AID1147382 | Increase in liver weight in Wistar rat at 591 umol/kg/day administered through diet for 4 days | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6 | 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||